Live feed08:00:00·52dPRReleasevia QuantisnowTheriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal AdenocarcinomaByQuantisnow·Wall Street's wire, on your screen.TOVX· Theriva Biologics Inc.Health Care
